Developing glucose responsive insulins has been a key area of focus for Novo Nordisk.

On 17 August Novo Nordisk announced the complete acquisition of Ziylo, a University of Bristol spinout company, for $800 million.

The acquisition gives Novo Nordisk full rights to Ziylo’s glucose binding molecule technology, allowing it to develop glucose responsive insulins.

Developing glucose responsive insulins has been a key area of focus for Novo Nordisk, as these insulins will help create a safer therapy by eliminating the main risk associated with insulin therapy: hypoglycaemia.

These insulins can also make therapy more effective, as elimination of hypoglycaemia can lead to better metabolic control, thereby reducing the burden of diabetes for people living with the disease.

Regarding the acquisition, the chief executive officer and co-founder of Ziylo, Harry Destecroix, said “Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications, and it brings hope of a truly groundbreaking treatment to diabetes patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the global diabetes care market, Novo Nordisk is the market leader with 27% of the market share.

With the recent acquisition, Novo Nordisk aspires to realise the world’s first glucose responsive insulin, which would help it to stay ahead in the market.

For more insight and data, visit the GBI Research report store.